Skip to main content

Clonazepam Disease Interactions

There are 10 disease interactions with clonazepam.

Major

Benzodiazepines (applies to clonazepam) acute alcohol intoxication

Major Potential Hazard, High plausibility.

The use of benzodiazepines with alcohol is not recommended. Patients with acute alcohol intoxication exhibit depressed vital signs. The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur. Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.

References

  1. (2002) "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn
  2. (2002) "Product Information. Valium (diazepam)." Roche Laboratories
  3. (2002) "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories
  5. (2001) "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation
  6. (2001) "Product Information. Halcion (triazolam)." Pharmacia and Upjohn
  7. (2001) "Product Information. Dalmane (flurazepam)." Roche Laboratories
  8. (2001) "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical
  9. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
  10. (2022) "Product Information. Prosom (estazolam)." Abbott Pharmaceutical
  11. (2001) "Product Information. Librium (chlordiazepoxide)." Roche Laboratories
  12. (2001) "Product Information. Doral (quazepam)." Wallace Laboratories
  13. (2001) "Product Information. Versed (midazolam)." Roche Laboratories
  14. (2011) "Product Information. Onfi (clobazam)." Lundbeck Inc
View all 14 references
Major

Benzodiazepines (applies to clonazepam) closed-angle glaucoma

Major Potential Hazard, Low plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension

The manufacturers consider the use of benzodiazepines to be contraindicated in patients with acute angle-closure glaucoma or untreated open-angle glaucoma. These agents do not possess anticholinergic activity but have very rarely been associated with increased intraocular pressure.

References

  1. (2002) "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn
  2. (2002) "Product Information. Valium (diazepam)." Roche Laboratories
  3. (2002) "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories
  5. (2001) "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation
  6. (2001) "Product Information. Halcion (triazolam)." Pharmacia and Upjohn
  7. (2001) "Product Information. Dalmane (flurazepam)." Roche Laboratories
  8. (2001) "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical
  9. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
  10. (2022) "Product Information. Prosom (estazolam)." Abbott Pharmaceutical
  11. (2001) "Product Information. Librium (chlordiazepoxide)." Roche Laboratories
  12. (2001) "Product Information. Doral (quazepam)." Wallace Laboratories
  13. (2001) "Product Information. Versed (midazolam)." Roche Laboratories
  14. Fraunfelder FT, Fraunfelder FW; Randall JA (2001) "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann
View all 14 references
Major

Benzodiazepines (applies to clonazepam) drug dependence

Major Potential Hazard, High plausibility. Applicable conditions: Drug Abuse/Dependence

Benzodiazepines have the potential to cause dependence and abuse. Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages. However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms. Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines. It may be prudent to refrain from dispensing large quantities of medication to these patients. After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule. If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.

References

  1. (2002) "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn
  2. (2002) "Product Information. Valium (diazepam)." Roche Laboratories
  3. (2002) "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories
  5. (2001) "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation
  6. (2001) "Product Information. Halcion (triazolam)." Pharmacia and Upjohn
  7. (2001) "Product Information. Dalmane (flurazepam)." Roche Laboratories
  8. (2001) "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical
  9. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
  10. (2022) "Product Information. Prosom (estazolam)." Abbott Pharmaceutical
  11. (2001) "Product Information. Librium (chlordiazepoxide)." Roche Laboratories
  12. (2001) "Product Information. Doral (quazepam)." Wallace Laboratories
  13. (2011) "Product Information. Onfi (clobazam)." Lundbeck Inc
  14. (2020) "Product Information. Byfavo (remimazolam)." Acacia Pharma, Inc
View all 14 references
Major

Benzodiazepines (applies to clonazepam) respiratory depression

Major Potential Hazard, High plausibility. Applicable conditions: Asphyxia, Pulmonary Impairment, Respiratory Arrest

Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration. However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders. Therapy with benzodiazepines should be administered cautiously in these patients. Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used. Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.

References

  1. Iber FL, Livak A, Kruss DM (1992) "Apnea and cardiopulmonary arrest during and after endoscopy." J Clin Gastroenterol, 14, p. 109-13
  2. Cohen S, Khan A (1987) "Respiratory distress with use of lorazepam in mania." J Clin Psychopharmacol, 7, p. 199-200
  3. Donaldson D, Gibson G (1980) "System complications with intravenous diazepam." Oral Surg Oral Med Oral Patho, 49, p. 126-30
  4. Eldridge PR, Punt JA (1990) "Risks associated with giving benzodiazepines to patients with acute neurological injuries." Br Med J, 300, p. 1189-90
  5. Man GC, Hsu K, Sproule BJ (1986) "Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease." Chest, 90, p. 832-6
  6. Mendelson WB, Weingartner H, Greenblatt DJ, Garnett D, Gillin JC (1982) "A clinical study of flurazepam." Sleep, 5, p. 350-60
  7. (2002) "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn
  8. (2002) "Product Information. Valium (diazepam)." Roche Laboratories
  9. (2002) "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories
  10. (2001) "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories
  11. (2001) "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation
  12. Pierce MW, Shu VS, Groves LJ (1990) "Safety of estazolam. The United States clinical experience." Am J Med, 88, s12-7
  13. Skatrud JB, Badr S, Begle RL, Juan D (1990) "Ventilatory response to single, high dose estazolam in healthy humans." J Clin Pharmacol, 30, p. 543-8
  14. Sullivan RJ, Jr (1989) "Respiratory depression requiring ventilatory support following 0.5 mg of triazolam." J Am Geriatr Soc, 37, p. 450-2
  15. (2001) "Product Information. Halcion (triazolam)." Pharmacia and Upjohn
  16. (2001) "Product Information. Dalmane (flurazepam)." Roche Laboratories
  17. Model DG, Berry DJ (1974) "Effects of chlordiazepoxide in respiratory failure due to chronic bronchitis." Lancet, 2, p. 869-70
  18. Dixon D (1985) "Respiratory depression following midazolam." Anaesthesia, 40, p. 922
  19. Yakel DL, Jr Whittaker SE, Elstad MR (1992) "Midazolam-induced angioedema and bronchoconstriction." Crit Care Med, 20, p. 307-8
  20. Berggren L, Eriksson I, Mollenholt P, Sunzel M (1987) "Changes in respiratory pattern after repeated doses of diazepam and midazolam in healthy subjects." Acta Anaesthesiol Scand, 31, p. 667-72
  21. Taylor JW, Simon KB (1990) "Possible intramuscular midazolam-associated cardiorespiratory arrest and death." DICP, 24, p. 695-7
  22. Munoz HR, Dagnino JA, Rufs JA, Bugedo GJ (1992) "Benzodiazepine premedication causes hypoxemia during spinal anesthesia in geriatric patients." Reg Anesth, 17, p. 139-42
  23. (2001) "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical
  24. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
  25. (2022) "Product Information. Prosom (estazolam)." Abbott Pharmaceutical
  26. (2001) "Product Information. Librium (chlordiazepoxide)." Roche Laboratories
  27. Murphy PJ, Erskine R, Langton JA (1994) "The effect of intravenously administered diazepam, midazolam and flumazenil on the sensitivity of upper airway reflexes." Anaesthesia, 49, p. 105-10
  28. (2001) "Product Information. Doral (quazepam)." Wallace Laboratories
  29. (2001) "Product Information. Versed (midazolam)." Roche Laboratories
  30. Berry RB, Kouchi K, Bower J, Prosise G, Light RW (1995) "Triazolam in patients with obstructive sleep apnea." Am J Respir Crit Care Med, 151, p. 450-4
  31. (2020) "Product Information. Byfavo (remimazolam)." Acacia Pharma, Inc
View all 31 references
Major

Benzodiazepines (applies to clonazepam) seizures

Major Potential Hazard, Moderate plausibility.

The use of benzodiazepines in patients with seizure disorders may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal). Appropriate anticonvulsant medication might need to be initiated or the dosage increased. Abrupt cessation of benzodiazepine therapy may precipitate seizures and other withdrawal symptoms, particularly after prolonged use and/or excessive dosages. Status epilepticus may occur in patients with a history of seizures withdrawn rapidly from benzodiazepine therapy. Following chronic administration, cessation of benzodiazepine therapy should occur gradually with incrementally reduced dosages. Patients should be advised not to discontinue medication without first consulting with the physician.

References

  1. Ananth J (1983) "Abstinence syndrome from therapeutic doses of oxazepam." Can J Psychiatry, 28, p. 592
  2. Wilbur R, Kulik AV (1983) "Abstinence syndrome from therapeutic doses of oxazepam." Can J Psychiatry, 28, p. 298-300
  3. Busto U, Sellers EM, Naranjo CA, et al. (1986) "Withdrawal reaction after long-term therapeutic use of benzodiazepines." N Engl J Med, 315, p. 854-9
  4. Hersch EL, Billings RF (1988) "Acute confusional state with status petit mal as a withdrawal syndrome: and five year follow-up." Can J Psychiatry, 33, p. 157-9
  5. Howe JG (1980) "Lorazepam withdrawal seizures." Br Med J, 280, p. 1163-4
  6. Kales A, Bixler EO, Soldatos CR, Jacoby JA, Kales JD (1986) "Lorazepam: effects on sleep and withdrawal phenomena." Pharmacology, 32, p. 121-30
  7. Robinson GM, Sellers EM (1982) "Diazepam withdrawal seizures." Can Med Assoc J, 126, p. 944-5
  8. Browne JL, Hauge KJ (1986) "A review of alprazolam withdrawal." Drug Intell Clin Pharm, 20, p. 837-41
  9. Ghadirian AM, Gauthier S, Wong T (1987) "Convulsions in patients abruptly withdrawn from clonazepam while receiving neuroleptic medication ." Am J Psychiatry, 144, p. 686
  10. Hauser P, Devinsky O, De Bellis M, Theodore WH, Post RM (1989) "Benzodiazepine withdrawal delirium with catatonic features. Occurrence in patients with partial seizure disorders." Arch Neurol, 46, p. 696-9
  11. Specht U, Boenigk HE, Wolf P (1989) "Discontinuation of clonazepam after long-term treatment." Epilepsia, 30, p. 458-63
  12. Alvarez N, Hartford E, Doubt C (1981) "Epileptic seizures induced by clonazepam." Clin Electroencephalogr, 12, p. 57-65
  13. Berlin RM, Conell LJ (1983) "Withdrawal symptoms after long-term treatment with therapeutic doses of flurazepam: a case report." Am J Psychiatry, 140, p. 488-90
  14. Bond WS, Schwartz M (1984) "Withdrawal reactions after long-term treatment with flurazepam." Clin Pharm, 3, p. 316-8
  15. (2002) "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn
  16. (2002) "Product Information. Valium (diazepam)." Roche Laboratories
  17. (2002) "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories
  18. (2001) "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories
  19. (2001) "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation
  20. Tien AY, Gujavarty KS (1985) "Seizure following withdrawal from triazolam." Am J Psychiatry, 142, p. 1516-7
  21. Patterson WM (1988) "Triazolam withdrawal." J Clin Psychiatry, 49, p. 369
  22. Schneider LS, Syapin PJ, Pawluczyk S (1987) "Seizures following triazolam withdrawal despite benzodiazepine treatment." J Clin Psychiatry, 48, p. 418-9
  23. (2001) "Product Information. Halcion (triazolam)." Pharmacia and Upjohn
  24. (2001) "Product Information. Dalmane (flurazepam)." Roche Laboratories
  25. Ryan GP, Boisse NR (1983) "Experimental induction of benzodiazepine tolerance and physical dependence." J Pharmacol Exp Ther, 226, p. 100-7
  26. Petursson H, Lader MH (1981) "Benzodiazepine dependence." Br J Addict, 76, p. 133-45
  27. Finley PR, Nolan PE, Jr (1989) "Precipitation of benzodiazepine withdrawal following sudden discontinuation of midazolam." DICP, 23, p. 151-2
  28. (2001) "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical
  29. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
  30. (2022) "Product Information. Prosom (estazolam)." Abbott Pharmaceutical
  31. (2001) "Product Information. Librium (chlordiazepoxide)." Roche Laboratories
  32. Roy-Byrne PP, Sullivan MD, Cowley DS, Ries RK (1993) "Adjunctive treatment of benzodiazepine discontinuation syndromes - a review." J Psychiatr Res, 27 Suppl, p. 143-53
  33. (2001) "Product Information. Doral (quazepam)." Wallace Laboratories
  34. (2001) "Product Information. Versed (midazolam)." Roche Laboratories
  35. Frattola L, Garreau M, Piolti R, Bassi S, Albizzati MG, Borghi C, Morselli PL (1994) "Comparison of the efficacy, safety and withdrawal of alpidem and alprazolam in anxious patients." Br J Psychiatry, 165, p. 94-100
View all 35 references
Major

Clonazepam (applies to clonazepam) renal/liver disease

Major Potential Hazard, High plausibility. Applicable conditions: Renal Dysfunction

The use of clonazepam is considered by the manufacturer to be contraindicated in patients with clinical or biochemical evidence of significant liver disease. Clonazepam is primarily metabolized by the liver, and the metabolites are eliminated by the kidney. Due to the possibility of excess accumulation of metabolites and the unknown effects of such accumulation, therapy with clonazepam should also be administered cautiously in patients with renal impairment.

References

  1. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
Moderate

Antiepileptics (applies to clonazepam) suicidal tendency

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis, Depression

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. AEDs should be administered cautiously in patients with depression or other psychiatric disorders; phentermine-topiramate should be avoided in patients with history of suicidal attempts or active suicidal ideation. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.

References

  1. (2002) "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals
  2. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
  3. (2001) "Product Information. Dilantin (phenytoin)." Parke-Davis
  4. (2001) "Product Information. Cerebyx (fosphenytoin)." Parke-Davis
  5. (2001) "Product Information. Mysoline (primidone)." Elan Pharmaceuticals
  6. (2005) "Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group
  7. (2009) "Product Information. Sabril (vigabatrin)." Lundbeck Inc
  8. (2011) "Product Information. Potiga (ezogabine)." GlaxoSmithKline
  9. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  10. (2016) "Product Information. Briviact (brivaracetam)." UCB Pharma Inc
  11. (2018) "Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC
  12. (2020) "Product Information. Xcopri (cenobamate)." SK Life Science, Inc.
  13. (2020) "Product Information. Fintepla (fenfluramine)." Zogenix, Inc
  14. (2022) "Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc
  15. (2022) "Product Information. Diacomit (stiripentol)." Biocodex USA, SUPPL-3
  16. (2023) "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc, SUPPL-23
  17. (2023) "Product Information. Topamax (topiramate)." Janssen Pharmaceuticals, SUPPL-65
View all 17 references
Moderate

Benzodiazepines (applies to clonazepam) depression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis

Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation. Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents. Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References

  1. (2002) "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn
  2. (2002) "Product Information. Valium (diazepam)." Roche Laboratories
  3. (2002) "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories
  5. (2001) "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation
  6. (2001) "Product Information. Halcion (triazolam)." Pharmacia and Upjohn
  7. (2001) "Product Information. Dalmane (flurazepam)." Roche Laboratories
  8. (2001) "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical
  9. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
  10. (2022) "Product Information. Prosom (estazolam)." Abbott Pharmaceutical
  11. (2001) "Product Information. Librium (chlordiazepoxide)." Roche Laboratories
  12. (2001) "Product Information. Doral (quazepam)." Wallace Laboratories
  13. (2011) "Product Information. Onfi (clobazam)." Lundbeck Inc
View all 13 references
Moderate

Benzodiazepines (applies to clonazepam) obesity

Moderate Potential Hazard, Moderate plausibility.

The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat. Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam. Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status. Longer dosing intervals may be appropriate. When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.

References

  1. (2002) "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn
  2. (2002) "Product Information. Valium (diazepam)." Roche Laboratories
  3. (2002) "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories
  5. (2001) "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation
  6. (2001) "Product Information. Halcion (triazolam)." Pharmacia and Upjohn
  7. (2001) "Product Information. Dalmane (flurazepam)." Roche Laboratories
  8. (2001) "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical
  9. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
  10. (2022) "Product Information. Prosom (estazolam)." Abbott Pharmaceutical
  11. (2001) "Product Information. Librium (chlordiazepoxide)." Roche Laboratories
  12. (2001) "Product Information. Doral (quazepam)." Wallace Laboratories
  13. (2001) "Product Information. Versed (midazolam)." Roche Laboratories
  14. American Medical Association, Division of Drugs and Toxicology (1994) "Drug evaluations annual 1994." Chicago, IL: American Medical Association;
View all 14 references
Moderate

Benzodiazepines (applies to clonazepam) paradoxical reactions

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hyperkinetic Syndrome of Childhood, Psychosis

Paradoxical reactions, including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares and vivid dreams, have been reported with the use of benzodiazepines in psychiatric patients and pediatric patients with hyperactive aggressive disorders. Such patients should be monitored for signs of paradoxical stimulation during therapy with benzodiazepines. The manufacturers do not recommend the use of benzodiazepines for the treatment of psychosis.

References

  1. French AP (1989) "Dangerously aggressive behavior as a side effect of alprazolam." Am J Psychiatry, 146, p. 276
  2. Goodman WK, Charney DS (1987) "A case of alprazolam, but not lorazepam, inducing manic symptoms." J Clin Psychiatry, 48, p. 117-8
  3. Edwards JG, Inman WH, Pearce GL, Rawson NS (1991) "Prescription-event monitoring of 10,895 patients treated with alprazolam." Br J Psychiatry, 158, p. 387-92
  4. Wysowski DK, Barash D (1991) "Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration's Spontaneous Reporting System." Arch Intern Med, 151, p. 2003-8
  5. Bixler EO, Kales A, Brubaker BH, Kales JD (1987) "Adverse reactions to benzodiazepine hypnotics: spontaneous reporting system." Pharmacology, 35, p. 286-300
  6. Cohen LS, Rosenbaum JF (1987) "Clonazepam: new uses and potential problems." J Clin Psychiatry, 48, p. 50-6
  7. White MC, Silverman JJ, Harbison JW (1982) "Psychosis associated with clonazepam therapy for blepharospasm." J Nerv Ment Dis, 170, p. 117-9
  8. Dorevitch A (1991) "Mania associated with clonazepam." DICP, 25, p. 938-9
  9. Marchevsky S, Isaacs G, Nitzan I (1988) "Behavioral disinhibition with clonazepam." Gen Hosp Psychiatry, 10, p. 447
  10. Binder RL (1987) "Three case reports of behavioral disinhibition with clonazepam." Gen Hosp Psychiatry, 9, p. 151-3
  11. Koczerginski D, Kennedy SH, Swinson RP (1989) "Clonazepam and lithium--a toxic combination in the treatment of mania?" Int Clin Psychopharmacol, 4, p. 195-9
  12. Fava M, Borofsky GF (1991) "Sexual disinhibition during treatment with a benzodiazepine: a case report." Int J Psychiatry Med, 21, p. 99-104
  13. Cunningham TA (1975) "Letter: Adverse reaction to flurazepam." Can Med Assoc J, 112, p. 805
  14. Pollack MH (1987) "Clonazepam: a review of open clinical trials." J Clin Psychiatry, 48, p. 12-5
  15. (2002) "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn
  16. (2002) "Product Information. Valium (diazepam)." Roche Laboratories
  17. (2002) "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories
  18. (2001) "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories
  19. (2001) "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation
  20. Karch FE (1979) "Rage reaction associated with clorazepate dipotassium." Ann Intern Med, 91, p. 61-2
  21. Weilburg JB, Sachs G, Falk WE (1987) "Triazolam-induced brief episodes of secondary mania in a depressed patient." J Clin Psychiatry, 48, p. 492-3
  22. Rothschild AJ (1992) "Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature." J Clin Psychiatry, 53, p. 69-79
  23. Schogt B, Conn D (1985) "Paranoid symptoms associated with triazolam." Can J Psychiatry, 30, p. 462-3
  24. (2001) "Product Information. Halcion (triazolam)." Pharmacia and Upjohn
  25. (2001) "Product Information. Dalmane (flurazepam)." Roche Laboratories
  26. Viscott DS (1968) "Chlordiazepoxide and hallucinations. Report of cases." Arch Gen Psychiatry, 19, p. 370-6
  27. Fiset L, Milgrom P, Beirne OR, Roy-Byrne P (1992) "Disinhibition of behaviors with midazolam: report of a case." J Oral Maxillofac Surg, 50, p. 645-9
  28. Lobo BL, Miwa LJ (1988) "Midazolam disinhibition reaction." Drug Intell Clin Pharm, 22, p. 725
  29. (2001) "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical
  30. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
  31. (2022) "Product Information. Prosom (estazolam)." Abbott Pharmaceutical
  32. (2001) "Product Information. Librium (chlordiazepoxide)." Roche Laboratories
  33. Rush CR, Higgins ST, Hughes JR, Bickel WK (1993) "A comparison of the acute behavioral effects of triazolam and temazepam in normal volunteers." Psychopharmacology (Berl), 112, p. 407-14
  34. (2001) "Product Information. Doral (quazepam)." Wallace Laboratories
  35. (2001) "Product Information. Versed (midazolam)." Roche Laboratories
View all 35 references

Clonazepam drug interactions

There are 525 drug interactions with clonazepam.

Clonazepam alcohol/food interactions

There are 2 alcohol/food interactions with clonazepam.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.